<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 29 Mar 2021 07:21:34 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>严重副作用不同疾病的对应手册（面向患者·公众）（60）-周围神经病变</title><link>https://mp.weixin.qq.com/s/T03A1fmFJH1hSaTgNLXA-Q</link><description></description><content:encoded><![CDATA[严重副作用不同疾病的对应手册（面向患者·公众）（60）-周围神经病变]]></content:encoded><pubDate>Sun, 28 Mar 2021 19:53:11 +0800</pubDate></item><item><title>药品专利期限补偿制度红利能否惠及已上市新药引关注专家建议</title><link>https://mp.weixin.qq.com/s/o2hnd8YYu4U4wjIzl6Ss0g</link><description></description><content:encoded><![CDATA[药品专利期限补偿制度红利能否惠及已上市新药引关注专家建议]]></content:encoded><pubDate>Sun, 28 Mar 2021 19:53:11 +0800</pubDate></item><item><title>种族差异性药物桥接境外临床研究数据辅助新药审评工作的启示——以盐酸胍法辛在日本上市为例</title><link>https://mp.weixin.qq.com/s/2HDTQmise784RLBVCU6jeQ</link><description></description><content:encoded><![CDATA[种族差异性药物桥接境外临床研究数据辅助新药审评工作的启示——以盐酸胍法辛在日本上市为例]]></content:encoded><pubDate>Sun, 28 Mar 2021 19:53:11 +0800</pubDate></item><item><title>CDE常见一般性技术问题124个问题解答</title><link>https://mp.weixin.qq.com/s/sIUVBHyQkgKKHaQePOaaJg</link><description></description><content:encoded><![CDATA[CDE常见一般性技术问题124个问题解答]]></content:encoded><pubDate>Sat, 27 Mar 2021 22:01:35 +0800</pubDate></item><item><title>美国仿制药立项调研及评估</title><link>https://mp.weixin.qq.com/s/q3aZYjKg9KnHzKDPLZvN8A</link><description></description><content:encoded><![CDATA[美国仿制药立项调研及评估]]></content:encoded><pubDate>Sat, 27 Mar 2021 22:01:35 +0800</pubDate></item><item><title>NMPA发布《医疗器械注册管理办法（修订草案征求意见稿）》</title><link>https://mp.weixin.qq.com/s/X9cq7DX5iADeOxFuSwnrkw</link><description></description><content:encoded><![CDATA[NMPA发布《医疗器械注册管理办法（修订草案征求意见稿）》]]></content:encoded><pubDate>Fri, 26 Mar 2021 23:39:46 +0800</pubDate></item><item><title>双抗，下一代抗体药物</title><link>https://mp.weixin.qq.com/s/nqgnXXxGwgsIRli_fBMyNw</link><description></description><content:encoded><![CDATA[双抗，下一代抗体药物]]></content:encoded><pubDate>Fri, 26 Mar 2021 23:39:46 +0800</pubDate></item><item><title>“现货”CAR-T细胞疗法引领全球浪潮</title><link>https://mp.weixin.qq.com/s/zWgB0uel6KO0shwPVFUL-A</link><description></description><content:encoded><![CDATA[“现货”CAR-T细胞疗法引领全球浪潮]]></content:encoded><pubDate>Fri, 26 Mar 2021 23:39:46 +0800</pubDate></item><item><title>无菌生产工艺验证的主要内容与方法</title><link>https://mp.weixin.qq.com/s/aVl8z7armTvyV4SLWhCKPA</link><description></description><content:encoded><![CDATA[无菌生产工艺验证的主要内容与方法]]></content:encoded><pubDate>Thu, 25 Mar 2021 19:57:34 +0800</pubDate></item><item><title>小分子药物研发中代谢产物非临床研究的关注要点</title><link>https://mp.weixin.qq.com/s/0yptUk_PM4ynSMRyyyGiCA</link><description></description><content:encoded><![CDATA[小分子药物研发中代谢产物非临床研究的关注要点]]></content:encoded><pubDate>Thu, 25 Mar 2021 19:57:34 +0800</pubDate></item><item><title>大脑里5个肿瘤消失了！CAR-T细胞疗法见证奇迹</title><link>https://mp.weixin.qq.com/s/IwD2tqsuG6rV7yJZaj-bcw</link><description></description><content:encoded><![CDATA[大脑里5个肿瘤消失了！CAR-T细胞疗法见证奇迹]]></content:encoded><pubDate>Thu, 25 Mar 2021 19:57:34 +0800</pubDate></item><item><title>走进Lonza，聊一聊药物早期开发的那些事儿</title><link>https://mp.weixin.qq.com/s/_RXxjxi4xcuAiTV5kDcdjA</link><description></description><content:encoded><![CDATA[走进Lonza，聊一聊药物早期开发的那些事儿]]></content:encoded><pubDate>Thu, 25 Mar 2021 19:57:34 +0800</pubDate></item><item><title>胶囊剂溶出度方法及影响因素的探讨</title><link>https://mp.weixin.qq.com/s/Ui-C-sjXnjtXnNYaGg0BlA</link><description></description><content:encoded><![CDATA[胶囊剂溶出度方法及影响因素的探讨]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:25:25 +0800</pubDate></item><item><title>药审中心各类适应症项目管理人员联系方式更新了！</title><link>https://mp.weixin.qq.com/s/bDGccsoms5G9Gb36CapHZw</link><description></description><content:encoded><![CDATA[药审中心各类适应症项目管理人员联系方式更新了！]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:25:25 +0800</pubDate></item><item><title>化学药物生产现场检查问答总结</title><link>https://mp.weixin.qq.com/s/xF-DZ2qyqIS0VmLDoRB_Fg</link><description></description><content:encoded><![CDATA[化学药物生产现场检查问答总结]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:25:25 +0800</pubDate></item><item><title>完善药品专利强制许可实施程序的思考</title><link>https://mp.weixin.qq.com/s/eh71c7x_ga6zWwy_IK0McQ</link><description></description><content:encoded><![CDATA[完善药品专利强制许可实施程序的思考]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:25:25 +0800</pubDate></item><item><title>GMP知识培训课件ppt</title><link>https://mp.weixin.qq.com/s/GXYxs6GhTE5PEOWzawLbvA</link><description></description><content:encoded><![CDATA[GMP知识培训课件ppt]]></content:encoded><pubDate>Tue, 23 Mar 2021 19:57:43 +0800</pubDate></item><item><title>中国抗体药物被哪些技术“卡”住了脖子？</title><link>https://mp.weixin.qq.com/s/s-YhOXWrWulFgl9ZPEXfvg</link><description></description><content:encoded><![CDATA[中国抗体药物被哪些技术“卡”住了脖子？]]></content:encoded><pubDate>Tue, 23 Mar 2021 19:57:43 +0800</pubDate></item><item><title>药学申报资料该附哪些图谱？</title><link>https://mp.weixin.qq.com/s/I4_ptQ8sYMuayhoIejE66Q</link><description></description><content:encoded><![CDATA[药学申报资料该附哪些图谱？]]></content:encoded><pubDate>Tue, 23 Mar 2021 19:57:43 +0800</pubDate></item><item><title>聚焦小分子创新药FIC，罗氏/海思科/恒瑞/交大/复旦...PharmaCon首批嘉宾阵容曝光</title><link>https://mp.weixin.qq.com/s/VLu2g5tRWNpZz1BIEH-teQ</link><description></description><content:encoded><![CDATA[聚焦小分子创新药FIC，罗氏/海思科/恒瑞/交大/复旦...PharmaCon首批嘉宾阵容曝光]]></content:encoded><pubDate>Tue, 23 Mar 2021 19:57:43 +0800</pubDate></item></channel></rss>